A new competitor has entered the influenza vaccine market. Seqirus, a subsidiary of the Australia-based biotech firm CSL, will be entering the Korean market in earnest in the COVID-19 pandemic.

Seqirus Korea held an online press conference to celebrate the official launch of its Korean subsidiary on the 16th. At the conference, Seqirus threw its hat into the Korean flu vaccine market with its self-developed next-generation vaccine. At the conference, Gee-Seung Yoo, CEO of Seqirus Korea said, “Our global office is deeply interested in the significance and potential held by the Korean market. With our official launch, we hope to establish various partnerships in Korea.”

Seqirus is a vacc